|
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas. Approved GLP-1 agonists: * exenatide (Byetta/Bydureon), approved in 2005/2012 * liraglutide (Victoza, Saxenda), approved 2010 * lixisenatide (Lyxumia), approved in EU 2013 * albiglutide (Tanzeum), approved in 2014 by GSK * dulaglutide (Trulicity), approved in 2014 - manufactured by Eli Lily K Under investigation: 〔 * taspoglutide, phase III halted Sept 2010, These agents work in the same pathway as DPP-4 inhibitors but are generally considered more potent. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Glucagon-like peptide-1 agonist」の詳細全文を読む スポンサード リンク
|